.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB61_PeginterferonAlfa2aCombi.PeginterferonAlfa2aCombi .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB61_PeginterferonAlfa2aCombi.PeginterferonAlfa2aCombi| name: | PeginterferonAlfa2aCombinations |
| ATC code: | L03AB61 | route: | subcutaneous |
| n-compartments | 1 |
Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, an immunomodulatory agent used primarily in the treatment of chronic hepatitis B and C infections, often in combination with antiviral medications such as ribavirin. Peginterferon alfa-2a is still used, but its clinical use has declined with the advent of direct-acting antivirals.
Pharmacokinetic parameters have been evaluated mainly in adult patients with chronic hepatitis C, both male and female, generally aged 18–65 years, with or without cirrhosis, receiving subcutaneous weekly administration.
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650
Howell, CD, et al., & Hoofnagle, JH (2008). Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 6(5) 575–583. DOI:10.1016/j.cgh.2008.02.035 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18407798